Dyadic announces development and license agreement to commercialize animal-free alternative proteins using dapibus™

Jupiter, fla., sept. 19, 2023 (globe newswire) -- dyadic international, inc. (“dyadic”, “we”, “us”, “our”, or the “company”) (nasdaq: dyai), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet needs for effective, affordable and accessible biopharmaceutical products and alternative proteins for human and animal health, today announced that it entered into a development and exclusive license agreement to commercialize certain non-animal dairy enzymes used in the production of food products using dapibus™.
DYAI Ratings Summary
DYAI Quant Ranking